The UC Davis Cancer Center, an integrated program with Lawrence Livermore National Labs (LLNL), is a matrix organization under the aegis of the UC Davis Health System (combining the UC Davis School of Medicine and the UC Davis Medical Center), and the University of California, Davis. Located on the campus of the UC Davis Medical Center in Sacramento, California, the cancer center's administrative, clinical and research facilities are under the leadership of the Principal Investigator of this P30 competitive renewal;an initial P30 was awarded to the Cancer Center on July 1, 2002. The Cancer Center draws its 186 members from the faculty of UC Davis and investigators at the LLNL, the USDA Western Human Nutrition Research Center and the California Department of Public Health. Peer-reviewed funding for UC Davis Cancer Center members totals $81,918,736.00 of which $21,771,164.00 (direct costs) is provided by the NCI. Investigators at the other organizations contributing membership are also provided research funding through the US Department of Energy, the US Department of Agriculture, and the State of California respectively. At the UC Davis Cancer Center, research is organized into six programs: (1) Molecular Oncology, (2) Comparative Oncology, (3) Cancer Therapeutics, (4) Population Sciences and Health Disparities, (5) Prostate Cancer, (6) Biomedical Technology. This competitive renewal for the P30 [Cancer Center Support Grant] proposes support for (1) senior leadership, (2) program leadership, (3) developmental programs, (4) administration, (5) planning and evaluation activities, (6) nine shared resources including genomics, optical biology, mouse biology, the clinical trials support unit, biostatistics, clinical and molecular pharmacology, animal imaging, biospecimen repository and combinatorial chemistry, (7) the Protocol Review and Monitoring System, (8) protocol-specific research, and (9) Data Safety and Monitoring.

Public Health Relevance

The proposed Cancer Center Support Grant provides the infrastructure for the cancer research enterprise at UC Davis and for center members at other institutions. This infrastructure promotes collaboration and and scientific excellence in cancer research and the application of research to the care of patients benefiting from research at UC Davis and through dissemination, patients everywhere.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-11
Application #
8530168
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2002-07-01
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
11
Fiscal Year
2013
Total Cost
$3,034,249
Indirect Cost
$1,057,751
Name
University of California Davis
Department
Urology
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529

Showing the most recent 10 out of 836 publications